Navigation Links
Targeting aggressive breast cancers by putting them to sleep
Date:3/25/2008

It is well established that Id1, a gene normally produced only in embryonic development, is reactivated in many 'solid' cancers, or carcinomas.

In the case of breast cancer, the Id1 gene is active only in the more aggressive and metastatic varieties of cancer. Typically those cancers do not possess the oestrogen receptor, and for that reason cannot be treated with Tamoxifen (a drug that interferes with the action of oestrogen), the most effective breast cancer treatment available.

The outcomes for women with breast cancers producing Id1 are therefore much worse than for women with other forms of breast cancer.

Findings by Dr Alex Swarbrick, a scientist at Sydney's Garvan Institute of Medical Research, in collaboration with Professor J. Michael Bishop, Nobel Prize winner and Chancellor of the University of California San Francisco (UCSF), may provide hope for such women in the future. Their article, published online this week in the international journal Proceedings of the National Academy of Sciences, USA (PNAS), shows that Id1 drives some breast cancers.

Dr Swarbrick initiated the Id1 project three years ago while working as a post doctoral researcher in the laboratory of Professor Bishop He conducted much of the experimental work for the project at UCSF, then analysed the data and tissue samples at Garvan. "We happened to ask the right questions about the right gene," he said. "Up to that point, no-one else had asked whether or not Id1 actually contributed to the origin and behaviour of breast cancer".

"By artificially activating the Id1 protein in mouse mammary glands, we demonstrated that Id1 indeed contributes to cancer - and that mammary cancers with high levels of Id1 become very aggressive and highly metastatic."

"We also showed that if we genetically switch off the Id1 gene in an established tumour, those mice live much longer than mice with continual Id1 expression in their tumour. In fact about 40% of them were cured and the tumours just shrank away."

"One of our most surprising findings was that although the tumours went away, the cells making up the tumour didn't die, as you'd expect."

Instead, the vanishing tumours underwent 'senescence' a tumour suppressive mechanism that scientists are only just beginning to understand. The word is derived from the Latin 'senescere', to grow old. For cells, it means they permanently lose the ability to divide.

Swarbrick believes that as well as trying to kill aggressive breast cancers, it may also be effective to drive them into senescence, to put them to sleep. "You induce a terminal sleep, and then the immune system just gobbles them up."

"Many cancers mutate the genes involved in cell death, so it's hard to kill them. Our results suggest that in the future if we can therapeutically target the genes controlling senescence, such as Id1, we can force these tumours to senesce."


'/>"/>

Contact: Alison Heather
A.heather@garvan.org.au
61-292-958-128
Research Australia
Source:Eurekalert

Related medicine news :

1. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
2. Chronic infection persists by targeting stromal cell network in lymphoid organs
3. Prime Access Creates Groundbreaking Ads Targeting Urban Teens for the White Houses National Youth Anti-Drug Media Campaign
4. Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes
5. Phase I pharmacokinetic study of ECO-4601, a novel bifunctional targeting agent
6. Anticancer Drugs Targeting the ErbB (EGFr/HEr2) Pathway Alone Generated Global Sales of Nearly $5 Billion in the First Nine Months of 2007
7. Tobacco marketers targeting teens near schools
8. APIC launches Targeting Zero initiative to eradicate infections deemed preventable by CMS
9. New Research Shows Nutrition Programs Targeting Pregnancy and First 24 Months of Life Dramatically Improve Child Survival and Overall Health
10. Targeting gut bugs could revolutionize future drugs, say researcher
11. Targeting astrocytes slows disease progression in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... , ... Head Over Heels Athletic Arts’ gymnast, Brooklyn Varize, has qualified to ... at the University of Montana on April 28-May 1. Varize will compete on Saturday ... order to qualify, Varize needed to place top seven all-around in her respective age ...
(Date:4/28/2016)... ... April 28, 2016 , ... Trinity Health, ... Kids, a leading force in the fight to reduce tobacco use and its ... that can help reduce tobacco use. The initiative brings together two organizations committed ...
(Date:4/28/2016)... Illinois (PRWEB) , ... April ... ... the leading provider of enterprise Data Center Infrastructure Management solutions, announces today ... focuses on feature enhancements in the area of capacity management and optimization, ...
(Date:4/28/2016)... ... 28, 2016 , ... The American Society for Aesthetic Plastic ... the AnzuMedical™ Knowledge Sharing and Collaboration Platform™ , today announced a joint ... scheduled to launch in July 2016 and will be a combined effort between ...
(Date:4/28/2016)... ... 28, 2016 , ... Accreditation Commission for Health Care (ACHC) ... to develop a comprehensive Specialty Pharmacy Accreditation with Distinction in Oncology. This partnership ... provides a wide range of pharmacy accreditation services that assess the business as ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016 Dr. Vivek Ahuja ... and Ste phen Schmidt ... leading provider of cloud-based software solutions for life sciences, today announced ... bring a wealth of insight to a growing business.  This will ... George Phillips joined ArisGlobal in the position of ...
(Date:4/28/2016)... 28, 2016  ValGenesis, Inc., the market ... (VLMS) today announced that a prominent world ... of chronic kidney failure has selected ValGenesis ... corporate validation process. The global medical device ... to manage their validation processes electronically. Upon ...
(Date:4/27/2016)...  Hologic, Inc. (Nasdaq: HOLX ) ... fiscal second quarter ended March 26, 2016.  GAAP ... 41.2%, and non-GAAP diluted EPS of $0.47 increased ... a reported basis, and 6.3% on a constant ... good quarter, highlighted by 14.6% growth in non-GAAP ...
Breaking Medicine Technology: